Leo from United Kingdom

Registered at the short selling broker eToro, 4 minutes ago.

» Try eToro you too
67% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

AbbVie, Inc. (ABBV) shares information

Abbvie Inc

24h Change

0.45 %


Live rate: Market closed

Stock data per Tuesday 28 Mar, 2023

0.71 (+ 0.45%)
US Market is closed

Live Stock price in graph for Abbvie Inc (ABBV)

  • Latest Volume

    3,532,488 (-9.14 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    158.599 USD

  • Today low

    157.45 USD

  • 52 week high

    169.46 USD

  • 52 week low

    131.49 USD

  • YTD Change


Quick links


Latest news about Abbvie Inc

Below you can find the most recent news posts about Abbvie Inc, primarily from US and UK based news sources.

CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies

Tuesday, 28 March 2023, 17:39:52
CytomX Therapeutics (CTMX) stock fell ~15% on Tuesday after FY22 results missed estimates and the company said that AbbVie (ABBV) will not advance cancer drug CX-2029 into…
— Seeking Alpha

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

Tuesday, 28 March 2023, 17:35:14
CytomX Therapeutics Inc (NASDAQ: CTMX ) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV ) decided not to advance the drug into additional studies . CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement. AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology … Full story available on Benzinga.com
— Benzinga

Who Are Pfizer”s (PFE) Main Competitors?

Saturday, 25 March 2023, 18:38:05
Pfizer”s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.
— Investopedia

Better Buy: AbbVie vs. Johnson & Johnson

Saturday, 25 March 2023, 10:30:00
These pharma giants beat the bear market last year.
— The Motley Fool

Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen”s Respective IL-23 Entries, According to Spherix Global Insights

Saturday, 25 March 2023, 00:00:00

— Kwhen Finance

Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have ABBV available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.